**[Principles of Transparency and Best Practice]**

**Table of Contents**

1. Website

2. Name of Journal

3. Peer Review Process

4. Ownership and Management

5. Governing Body

6. Editorial Team and Contact Information

7. Copyright and Licensing

8. Author Fees

9. Process for Identification of and Dealing with Allegations of Research Misconduct

10. Research & Publication Ethics

11. Publishing Schedule

12. Open Access

13. Archiving

14. Revenue Sources

15. Advertising

16. Direct Marketing

**1. Website**

1) The URL address of official journal web site is <https://clinicalhypertension.biomedcentral.com/>

2) **Aims & Scope**

Clinical Hypertension is a peer-reviewed, open access journal that aims to publish in all areas of hypertension and vascular disorders. We aim to ensure the widest possible dissemination of research throughout the hypertension community.

The journal focuses on areas within vascular biology, cellular and molecular biology, clinical hypertension, epidemiology, nephrology, endocrinology, neuroscience, pharmacology, genetics, pediatric hypertension and basic science.

**3) Authorship**

*Clinical Hypertension* is compliant with the [Editorial Policies set by BMC](https://www.biomedcentral.com/getpublished/editorial-policies).

BMC policy on Authorship can be found [here](https://www.biomedcentral.com/getpublished/editorial-policies#authorship).

**2. Name of journal**

The official journal title is *Clinical Hypertension*. Abbreviated title is *Clin Hypertens*

*Clinical Hypertension* is a continuation of Journal of the Korean Society of Hypertension.

**3. Peer Review Process**

*Clinical Hypertension* operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.

**4. Ownership and Management**

1) Information about the ownership:

This journal is owned by the publisher, the Korean Society of Hypertension.

<http://www.koreanhypertension.org/eng/intro/intro>

2) Management team of a journal (2017-2024)

**Editor-in-Chief**

*Wook-Bum Pyun, Ewha Womans University Seoul Hospital, Korea, republic of.*

**Deputy Editors**

*Jae-Hyeong Park, Choongnam National University College of Medicine, Korea, republic of.*

*In-Jeong Cho, Ewha Womans University Seoul Hospital, Korea, republic of.*

*Hye-Moon Chung, Kyung Hee University Hospital, Korea, republic of.*

**5. Governing Body**

The governing body is the journal's editorial board.

<https://clinicalhypertension.biomedcentral.com/about/editorial-board>

**6. Editorial Team and Contact Information**

1) Updated Editorial masthead is available on the journal website.

<https://clinicalhypertension.biomedcentral.com/about/editorial-board>

2) Contact information

(a) Wook-Bum Pyun(Editor-in-Chief)

Ewha Womans University Seoul Hospital, Korea, republic of.

E-mail: pwb423@ewha.ac.kr

(b) Tae-Hee Kim(Editorial staff)

The Korean Society of Hypertension

1504 LG Twintel 2 508, Samseong-ro, Gangnam-gu, Seoul, 06169, Republic of Korea

E-mail: editor@koreanhypertension.org

(C) For questions regarding submission or submitted manuscripts, contact editorial office via the [journal’s submission system](https://www.editorialmanager.com/chyp) (click ‘contact us’ link on the top banner).

**7. Copyright and Licensing**

As authors of articles published in *Clinical Hypertension* you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

**8. Author Fees**

The publication costs for *Clinical Hypertension* are covered by Korean Society of Hypertension, so authors do not need to pay an article-processing charge.

**9. Process for Identification of and Dealing with Allegations of Research Misconduct**

*Clinical Hypertension* endorses the [Editorial Policies set by BMC](https://www.biomedcentral.com/getpublished/editorial-policies) and takes seriously all allegations of potential misconduct following [COPE guidelines](http://publicationethics.org/resources) to properly deal with cases of suspected misconduct.

**10. Ethics & Consent**

BMC Editorial Policies on Ethics & Consent can be found [here](https://www.biomedcentral.com/getpublished/editorial-policies#ethics+and+consent).

**11. Publication Schedule**

On-line (eISSN 2056-5909): CAP (Continuous Article Publication)

**12. Open Access**

*Clinical Hypertension* is listed in the [Directory of Open Access Journals (DOAJ)](https://doaj.org/).

All articles published in *Clinical Hypertension* are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found [here](https://www.biomedcentral.com/about/open-access).

**13. Archiving**

**Archival content** <http://www.koreanhypertension.org/journal/previous2>

*Clinical Hypertension* is a continuation of the *Journal of the Korean Society of Hypertension.* All previous contents (1995-2014) from the *Journal of the Korean Society of Hypertension* are freely available at [its official website.](http://www.koreanhypertension.org/journal/previous2)

**14. Revenue Sources**

Revenue sources of journal are from the support of the Korean Society of Hypertension.

**15. Advertising**

none

**16. Direct Marketing**

Journal propagation has been done through the journal web site and distribution of an introduction pamphlets on Hypertension conference. Invitations to submit a manuscript are usually focused on the speakers at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.